Enhanced circulation effector composition and method

Details Enhanced circulation effector composition and method Enhanced circulation effector composition and method

2006-12-19

2006-12-19

Huff, Sheela J. (Department: 1643)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Liposomes

C424S085100, C424S085200, C424S085400, C424S812000, C530S391100, C530S350000

Reexamination Certificate

active

07150882

ABSTRACT:
A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the bloodstream. The effector molecules are attached to the distal ends of the polymer chains. In one embodiment, the effector is polymyxin B, for treatment of septic shock.

REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4429008 (1984-01-01), Martin et al.
patent: 4948590 (1990-08-01), Hawrot et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5092885 (1992-03-01), Yamada et al.
patent: 5122614 (1992-06-01), Zalipsky
patent: 5140013 (1992-08-01), Gaudreault et al.
patent: 5149794 (1992-09-01), Yatvin et al.
patent: 5527528 (1996-06-01), Allen et al.
patent: 6180134 (2001-01-01), Zalipsky et al.
patent: 6326353 (2001-12-01), Zalipsky et al.
patent: 6586002 (2003-07-01), Zalipsky et al.
patent: 0 339 504 (1989-11-01), None
patent: 0 428 486 (1991-05-01), None
patent: WO 90/14103 (1990-11-01), None
Maruyama, Journal of Liposome Research 7(4) 363 (1997).
Blume, G., et al.,Biochimica et Biophysica Acta1149:180-184 (1993).
Cross, et al.,Infect Immun 61(7):2741-2747, (1993).
deAzavedo, J.C.S., et al., pp. 419-430 (1985).
Endo, S., et al.,Clinical Therapeutics 14(1):64-67 (1992).
Feist, W., et al.,FEMS Microbiology Immunology 8973-90 (1992).
Fitzer-SchillerReuter, G., “Centocor Stops Trials of Flagship Drug”, Washington Post Financial section, pp. D3Jan. 19, 1993.
Harris, et al.,Trends Biotechnol 11(2):42-44 (1993).
Hayashi, T., and Y. Ikada,Biotechnology and Polymers(C.G. Gebelein, Ed., Plenum Press, New York), pp. 321-332 (1991).
Hershfield, M.S., et al.,New England J. Med. 316(10):589-595 (1987).
Hird,Genes&Cancerpp. 183-189 (1990).
Hunefield, G.,Anaesthesiol Reanimat 14(3):131-153 (1989).
Iwamoto, Y., et al.,Science 238: 1132-1134 (1987).
Katre, N.V., et al.,Proc. Natl. Acad. Sci. USA 84:1487-1491 (1987).
Kawasaki, K., et al.,Biochemical and Biophysical Research Communications 174(3):1159-1162 (1991).
Klibanov, A.L., et al.,Am. J. Physiol. Suppl. 261:60-65 (1991).
Klibanov, A.L. and Huang, L.,Journal of Liposome Research 2(3):321-334 (1992).
Manson, W.L., et al., Burns 18(2):98-102 (1992).
Maruyama, K., et al.,Proc. Natl. Acad. Sci. USA 87:5744-5748 (1990).
Munster, A., et al.,J Bum Care Rehabil 10(4);327-330 (1989).
Murata, J., et al.,Int. J. Biol. Macromol. 11:97-99 (1989).
Nitecki, D.E., and L. Aldwin,Biotechnology and PolymersC.G. Gebelein, Ed., Plenum Press, New York) pp. 295-299 (1991).
Osband, et al.,Imm Today 11(6):193-195, (1990).
Saiki, I., et al.,Br. J. Cancer60:722-728 (1989).
Sastry, P.A., et al.,Journal of Bacteriology 164(2):571-577 (1985).
Tam, J.P.,Proc. Natl. Acad. Sci. USA 85:5409-5413 (1988).
Veronese, F.M., et al.,Applied Biochem. and Biotech. 11:141-149 (1985).
Zalipsky, S., et al.,Eur. Polym. J. 19(12):1177-1183 (1983).

Affiliated with

Also associated with

Rating

Enhanced circulation effector composition and method does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Enhanced circulation effector composition and method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhanced circulation effector composition and method will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3676660